eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
Rhea-AI Summary
eXoZymes (NASDAQ:EXOZ) CCO Damien Perriman detailed the commercial path for cell-free biomanufacturing and the company’s first spinout, NCTx, on the Grow Everything podcast on April 10, 2026. Perriman said NCTx targets a supplement pathway for NCT while evaluating pharmaceutical options.
The episode highlighted third-party validation: a 100-fold tech transfer with ~99% conversion and 99.6% purity of NCT, which Perriman described as proof of the cell-free platform’s scale-up and tech-transfer capability.
AI-generated analysis. Not financial advice.
Positive
- 100-fold third-party scale-up achieved with Cayman Chemical
- 99% conversion in NCT production reported
- 99.6% purity achieved in independent manufacturing run
- Spinout NCTx launched to commercialize NCT via supplement pathway
Negative
- None.
News Market Reaction – EXOZ
On the day this news was published, EXOZ gained 2.63%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.8% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $113.62M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EXOZ gained 9.09% while close peers were mixed: ADAG -3.87%, ARMP -3.92%, VTGN +1.29%, FATE +6.72%, TCRX flat. Momentum scanner shows only a few biotech names like MGNX and FATE moving up, with ATOS down, supporting a stock-specific move tied to EXOZ’s NCTx and cell-free commercialization messaging rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Full-year 2025 update | Positive | +12.4% | Detailed 2025 operating metrics, platform progress, and financing preparations. |
| Mar 25 | Results call announcement | Positive | +0.4% | Scheduled Q4 and full-year 2025 results webinar and investor access details. |
| Mar 18 | Cayman pilot validation | Positive | -2.5% | Reported 100-liter pilot with >99% purity and ~99% conversion for NCT. |
| Mar 12 | MISTA symposium preview | Positive | +1.3% | Announced CCO presentation on NCT scaling and cell-free enzyme production. |
| Feb 10 | Brand and focus refresh | Positive | -3.6% | Introduced refreshed brand and sharpened pharmaceutical and nutraceutical strategy. |
Recent EXOZ news often drew meaningful price reactions, with both positive and negative moves following operational updates and branding or validation milestones.
Over the last several weeks, EXOZ has reported multiple NCT and platform milestones. On Mar 18, a successful 100-liter Cayman Chemical pilot run with ~99% conversion and 99.6% purity drew a -2.46% move, while a broader 2025 update on Mar 31 triggered a +12.38% reaction. Branding and strategy news on Feb 10 saw a -3.57% move. Today’s podcast-focused announcement continues the theme of highlighting NCTx and the cell-free commercialization model.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-01-16 registers up to $50,000,000 of mixed securities, with usage evidenced by recent 424B filings on 2026-01-26 and 2026-04-09. Proceeds are earmarked for working capital, R&D, regulatory and clinical activities, and potential expansions, which may dilute existing shareholders if additional securities are issued.
Market Pulse Summary
This announcement emphasizes EXOZ’s NCTx spinout strategy and cell-free biomanufacturing model, highlighting prior third-party scale-up to a 100-fold process with ~99% conversion and 99.6% purity. It reinforces the focus on NCT as a first commercialization path via supplements while keeping pharmaceutical options open. Against a backdrop of recent validation runs, investor presentations, and an active $50,000,000 shelf, ongoing execution and partnership traction remain key metrics to watch.
Key Terms
cell-free biomanufacturing technical
preclinical medical
tech transfer technical
biomanufacturing technical
AI-generated analysis. Not financial advice.
LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural products.
The Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder. Previous episodes have featured guests - including key individuals from companies like NVIDIA, P&G, Robertet, and eXoZymes CEO, Michael Heltzen, discussing the impact of biomanufacturing on all industries.
In the episode, Perriman outlined why eXoZymes launched NCTx as a dedicated vehicle for NCT, while keeping eXoZymes focused on what it believes it does best: Developing better ways to manufacture difficult-to-access molecules with meaningful commercial potential.
"eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else's hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform." states CCO of eXoZymes, Damien Perriman.
CEO of MessagingLab, Karl Schmieder, adds, "The scale-up problem in industrial biology isn't an engineering problem. Often, it's a biology problem. Cells are unpredictable by nature but eXoZymes eliminates that variable. When your chemistry runs outside the cell, you can engineer it like a real industrial process."
During the interview, Perriman said NCT emerged as a strong candidate for eXoZymes' first spinout because it combined a naturally occurring molecule, encouraging preclinical interest, and a long-standing manufacturing challenge that had limited broader commercial development. He also discussed why the company is initially pursuing the supplement pathway for NCT, while continuing to evaluate longer-term pharmaceutical opportunities in parallel.
The conversation also highlighted eXoZymes' recent third-party validation work with Cayman Chemical, where the company's NCT production process was independently transferred and scaled 100-fold, achieving approximately
The full episode of Grow Everything is available through major podcast platforms, including YouTube, Apple, and Spotify.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and abundant alternative: exozymes.
Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant feedstock into valuable nutraceuticals and novel medicines.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more at exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes
SOURCE: eXoZymes Inc.
View the original press release on ACCESS Newswire